<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351117</url>
  </required_header>
  <id_info>
    <org_study_id>R-06-355</org_study_id>
    <secondary_id>250347647</secondary_id>
    <nct_id>NCT00351117</nct_id>
  </id_info>
  <brief_title>St. John's Wort in the Treatment of Raynaud's Phenomenon</brief_title>
  <official_title>A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the efficacy of St. John's Wort (SJW) as a supplement, in the treatment
      of Raynaud's phenomenon (RP). The investigators are hypothesizing that taking SJW 300mg, 3
      times a day will decrease the frequency, duration, and severity of RP attacks when compared
      to placebo.

      Patients with RP will answer questionnaires and self-evaluate their symptoms of RP as a
      baseline. Then they will be assigned to either a treatment (will receive SJW capsules) or
      placebo (will receive non-therapeutic capsules) group. They will be required to take their
      capsules, self-evaluate their progress and be evaluated every two weeks in a clinic. The
      treatment phase will last six weeks.

      This trial will be conducted in a way to mimic the normal usage of natural products. Patients
      will not be required to stop any current treatment for RP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Raynaud's Phenomenon (RP) is a common vasospastic problem of digital artery vessels causing
      pain and ischemic fingers (the fingers turn white and then blue and or red). It is considered
      primary when it is not associated with other conditions. Raynaud's symptoms that are
      associated with pathological underlying cause especially connective tissue diseases are
      defined as secondary Raynaud's and are usually more severe than primary symptoms. Selective
      Serotonin receptor inhibitors (SSRIs) have shown to be effective in decreasing the symptoms
      of RP.

      St. John's Wort (SJW) is an natural product that is presently approved by Health Canada for
      treatment of depression. It is believed that SJW would have mechanism of action very similar
      to SSRIs.

      This clinical trial will measure the efficiency of SJW in decreasing the frequency, duration
      and severity of RP attacks. SJW will be test as a supplement to other treatments already in
      place. 76 patients (38 with primary Raynaud's and half with secondary Raynaud's) will be
      recruited from the Rheumatology clinic of St. Joseph's Health Care in London, Ontario. The
      recruitment period will span 18 months. As they enter the trial, subjects will be assigned to
      a treatment or a placebo group according to a pre-set randomization schedule. This assignment
      will be stratified for primary or secondary Raynaud's and double-blinded (patient and
      investigator).

      The primary outcome measure (frequency, duration and severity) will be assessed by the
      patient on a daily basis using a journal provided by the investigator. Secondary outcome
      measures will include functions questionnaires (HAQ, SF-36, DASH) and biological markers of
      endothelial damage (V-CAM, I-CAM, VEGF, von Willebrand factor), will be conducted as a
      baseline and at the conclusion of the treatment phase.

      Patients participation will span 8-10 weeks. The first two weeks are a baseline measurement
      for the status of RP using the journals, questionnaires, and serum tests. The treatment
      period will last 6 weeks in which the subject will be taking the capsules that they have been
      assigned and will be evaluated for changes or side-effects every two weeks. At the last visit
      the questionnaires and serum test will be repeated.

      Other results which may arise from the trial are:

        -  The safety of SJW in rheumatology patients, by monitoring side-effects

        -  The attitude of rheumatology patients in using Natural Health Products, by a
           questionnaire

        -  Elucidating parts of the RP mechanism, by measuring bio-markers

        -  Differences between primary and secondary RP, by stratified randomization

      The results will be analyzed for all three primary outcome measures as a difference of
      between baseline and treatment. These differences will be compared between treatment and
      placebo and each will be stratified for primary vs. secondary and possibly other demographic
      data.

      This trial, if positive, will offer another treatment to RP patients. This option will
      possibly have less side-effects and be better accepted because it is a Natural Product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Raynaud's Phenomenon (RP) attacks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of RP attacks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of RP attacks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily functions questionnaires (HAQ, SF-36, DASH)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of endothelial damage (V-CAM, I-CAM, VEGF, etc.)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Raynaud's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>St. John's wort 300mg PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose in capsule matching the St. John's wort. 300mg PO TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's Wort</intervention_name>
    <description>SJW in capsule form 300 mg PO TID</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Webber natural brand, product number 5006.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>lactose in gelatin capsule that same as St. John's wort</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or Females between 16 and 70 years old

          -  Primary or secondary Raynaud's phenomenon, as diagnosed by a rheumatologist

          -  Clinical need for treatment of Raynaud's phenomenon

          -  Experiences at least 7 attacks per week

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Prior allergic reaction to St. John's Wort

          -  Pregnancy or possibility or pregnancy in the next 4 months

          -  Women that are currently breastfeeding

          -  Depression requiring treatment

          -  Use of SSRIs or other antidepressants with the exception of low dose amitriptyline
             used for reasons other than depression

          -  Use of drugs that are potentiated by St. John's Wort, such as cyclosporine, coumadin,
             digoxin, and theophylline. The complete list of contraindicated medications can be
             received from investigator

          -  Clinically significant non-compliance with past therapies

          -  Anticipated need for surgery (sympathectomy) in the next three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Pope, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine University of Western Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Clinic, St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.NIAMS.NIH.gov/Health_Info/Raynauds_Phenomenon/default.asp</url>
    <description>American website of institute of arthritis: general medical information on Raynaud's Disease</description>
  </link>
  <link>
    <url>http://www.raynauds.org.uk</url>
    <description>British site for Raynaud's patients: cover medical data as well as support programs</description>
  </link>
  <link>
    <url>http://incamresearch.ca</url>
    <description>Canadian complementary and alternative medicine research group: contains details on how to conduct a natural product trials and has a lot of resources.</description>
  </link>
  <link>
    <url>http://www.herbmed.org</url>
    <description>A database that is linked to MedLine and does searches for herbal medicine only.</description>
  </link>
  <link>
    <url>http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index_e.html</url>
    <description>Health Canada Natural Health product site: information on regulation and legislature</description>
  </link>
  <reference>
    <citation>Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000 Mar;15(2):61-8.</citation>
    <PMID>10759336</PMID>
  </reference>
  <reference>
    <citation>Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001 Sep;40(9):1038-43.</citation>
    <PMID>11561116</PMID>
  </reference>
  <reference>
    <citation>Pope J. Raynaud's phenomenon (primary). Clin Evid. 2003 Jun;(9):1339-48. Review. Update in: Clin Evid. 2003 Dec;(10):1444-53.</citation>
    <PMID>12967424</PMID>
  </reference>
  <reference>
    <citation>Bolte MA, Avery D. Case of fluoxetine-induced remission of Raynaud's phenomenon--a case report. Angiology. 1993 Feb;44(2):161-3.</citation>
    <PMID>8434812</PMID>
  </reference>
  <reference>
    <citation>Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000 Apr;22(4):411-9.</citation>
    <PMID>10823363</PMID>
  </reference>
  <reference>
    <citation>Pope JE, Prashker M, Anderson J. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J Rheumatol. 2004 Jan;31(1):140-9.</citation>
    <PMID>14705233</PMID>
  </reference>
  <reference>
    <citation>Jaffe IA. Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet. 1995 May 27;345(8961):1378.</citation>
    <PMID>7752794</PMID>
  </reference>
  <reference>
    <citation>Kn√ºppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry. 2004 Nov;65(11):1470-9. Review.</citation>
    <PMID>15554758</PMID>
  </reference>
  <reference>
    <citation>Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6.</citation>
    <PMID>12153829</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <last_update_submitted>July 10, 2009</last_update_submitted>
  <last_update_submitted_qc>July 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Janet Pope</name_title>
    <organization>Lawson Health Research Institute</organization>
  </responsible_party>
  <keyword>St. John's Wort</keyword>
  <keyword>Selective Serotonin Receptor Inhibitor</keyword>
  <keyword>Microvasculature</keyword>
  <keyword>Natural Health Products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

